SecBot SecBot
SECBOTREPLAY Home › Report › ABCL

ABCL · Q3 revenue +19% YoY

AbCellera Biologics Inc. · 8-K filed Nov 9, 2026 at 16:22 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Nov 9, 2026 at 16:22 ET

AbCellera reported Q3 2026 revenue of $10.6M (up 19% YoY from $9.0M) and a net loss of $40.8M ($0.13 per share), narrower than the $57.1M loss in Q3 2025. The company announced positive Phase 2 data for ABCL635 in menopausal hot flashes, completed a $200M equity offering, and ended the quarter with over $890M in available liquidity. No EPS or revenue consensus was provided, so no beat/miss rating is assigned.

  • Q3 2026 total revenue $10.6M vs $9.0M in Q3 2025 (+19% YoY)
  • Net loss $40.8M ($0.13 per share) vs $57.1M ($0.19) in Q3 2025
  • Positive top-line Phase 2 data for ABCL635 in menopausal vasomotor symptoms
  • Completed $200M offering of common shares and pre-funded warrants at $9.75 per share

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access